Hormonal
In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.
If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.
In patients with T2DM, the use of insulin and oral antidiabetic medications was associated with higher GLP-1RA utilization... insulin use was significantly associated with higher odds of GLP-1RA use across all time periods and sexes.
Why this rating
Strong statistical association (ORs ranging from 2.25 to 5.77) in a large, representative dataset.
Source
Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States
Samuel Chijioke Ofili et al. · Journal of Managed Care & Specialty Pharmacy · 2026
DOI 10.18553/jmcp.2026.32.2.166
More from this paper
- GLP-1 receptor agonist utilization for obesity has increased significantly and disproportionately among women compared to men, with obesity emerging as a key predictor of use specifically in female patients.Good
- Depression is uniquely and significantly associated with increased GLP-1RA utilization in women, suggesting a complex interplay between mental health comorbidities and medication access.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →